Fluofarma owns a High Content Screening platform based on automated Flow
Cytometry, unique in Europe and specifically
build on its request. This innovative platform is fully automated from
cell culture to data analysis.
► Fully Automated & Integrated
Platform: from cell culture to data analysis
► Functional measures using an
automated 96-well plate flow cytometer
► Multiplexing analysis:
measure of up to 3 parameters simultaneously in single cells
► Large Capacity: 2000
wells tested a day and 2500 cells analyzed individually per well
► Reproducibility: Highly
reliable tests (0.84 Z’-factor 0.91)
Roche adopts Fluofarma’s platform
October 19, 2009 – Fluofarma announced today that it entered into
a multi-year agreement with Roche.
Read
More